Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-05
2007-06-05
Solola, Taofiq (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C546S119000, C548S361100
Reexamination Certificate
active
10825611
ABSTRACT:
Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
REFERENCES:
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4219551 (1980-08-01), Seidelmann et al.
patent: 5539111 (1996-07-01), Petzoldt et al.
patent: 5814651 (1998-09-01), Duplantier et al.
patent: 5846514 (1998-12-01), Foster et al.
patent: 5869516 (1999-02-01), Arlt et al.
patent: 5935978 (1999-08-01), Fenton et al.
patent: 6136821 (2000-10-01), Hersperger
patent: 6235736 (2001-05-01), Ina et al.
patent: 6258833 (2001-07-01), Martins et al.
patent: 6334997 (2002-01-01), Foster et al.
patent: 6372777 (2002-04-01), Martins et al.
patent: 6403597 (2002-06-01), Wilson et al.
patent: 6423710 (2002-07-01), Martins et al.
patent: 6495154 (2002-12-01), Tam et al.
patent: 1 251 126 (2002-10-01), None
patent: 10-72415 (1998-03-01), None
patent: WO 92/19594 (1992-11-01), None
patent: WO 93/07141 (1993-04-01), None
patent: WO 93/25517 (1993-12-01), None
patent: WO 94/14742 (1994-07-01), None
patent: WO 95/28926 (1995-11-01), None
patent: WO 95/35282 (1995-12-01), None
patent: WO 97/25312 (1997-07-01), None
patent: WO 97/49702 (1997-12-01), None
patent: WO 98/58901 (1998-12-01), None
patent: WO 00/66562 (2000-11-01), None
patent: WO 01/40216 (2001-06-01), None
patent: WO 01/58895 (2001-08-01), None
patent: WO 01/68600 (2001-09-01), None
patent: WO 02/45749 (2002-06-01), None
patent: WO 03/087062 (2003-10-01), None
patent: WO 2004/007463 (2004-01-01), None
patent: WO 2004/094411 (2004-11-01), None
Database Bellstein, XP002367781, J. Chem. Soc., Perkin Trans. 1, 1477-1500, 1977.
International Search Report Dated Sep. 13, 2004.
Written Opinion of the Int'l. Searching Authority dated Apr. 16, 2004.
Database Caplus ′Online!, Chemical Abstracts Service, Columbus, OH, US; XP002294352, Accession No. 1978:6818.
Database Caplus ′Online!, Chemical Abstracts Service, Columbus, OH, US; XP002294353, Accession No. 125:114541.
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002294354, Accession No. BRN: 7622210.
Malcolm A. Halcrow, et al., “Metal complexes of sterically hindered pyrazolylpyridines. The single crystal X-ray structure of [Cu(L1)2]BF4(L1= 1-{pyrid-2-yl}-3-2′,5′-dimethoxyphenyl}pyrazole)”, Polyhedron, vol. 16, No. 24, pp. 4257-4264, 1997.
Japanese Patent Abstract No. 2001-039954, dated Feb. 13, 2001.
Nagakura et al., “Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats,”British Journal of Pharmacology, (2002) 135, 1783-1793.
Keller et al., “Synthesis and Structure-Activity Relationship ofN-Arylrolipram Derivatives as Inhibitors of PDE4 Isozymes,”Chem. Pharm. Bull., 49(8) 1009-1017 (2001).
Martin, “PDE4 inhibitors—A review of the recent patent literature,”Idrugs, 2001 4 (3):312-338.
Wang et al., “Expression, Purification, and Characterization of Human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D,”Biochemical and Biophysical Research Communications, 234, 320-324 (1997).
Meyers et al., “The Synthesis of Aracemic 4-Substituted Pyrrolidinones and 3-Substituted Pyrrolidines. An Asymmetric Synthesis of (−)-Rolipram,”J. Org. Chem., 1993, 58, 36-42.
Crossland, J., “Rolipram,”Drugs Of The Future, vol. 13, No. 1, 1988.
Langlois et al., “Synthesis of the Novel Antidepressant (R)-(−)-Rolipram,”Synthetic Communications, 27 (18), 3133-3144 (1997).
Robichaud et al., “Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret,”Neuropharmacology, 38 (1999) 289-297.
Houslay et al., “The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions,”Advance in Pharmacology, vol. 44, pp. 225-342 (1998).
Zhang et al., “Inhibition Of Cyclic AMP Phosphodiesterase (PDE4) Reverses Memory Deficits Associated with NMDA Receptor Antagonism,”Neuropsychopharmacology, 2000, 23, 198-204.
Zhang et al., “Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats,”Psychopharmacology DOI, 10.1007/s002130000414 (2000).
Barad et al., “Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory,”Proc. Natl. Acad. Sci., USA, vol. 95, pp. 15020-15025, Dec. 1998.
Demnitz et al., “Enantiodivergent Synthesis of (R)- and (S)-Rolipram,”Molecules, 1998, 3, 107-119.
Osby et al., “Rapid and Efficient Reduction of Aliphatic Nitro Compounds to Amines,”Tetrahedron Letters, vol. 26, No. 52, pp. 6413-6416, 1985.
Küsters et al., “Influence of temperature on the enantioseparation of rolipram and structurally related racemates on Chiracel-OD,”Journal of ChromatographyA, 737, (1996) 333-337.
Christensen et al., “1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma,”J. Med. Chem, 1998, 41, 821-835.
Krause et al., “Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences,”Xenobiotica, 1988, vol. 18, No. 5, 561-571.
Lourenco et al., “Characterization ofR-[11C]rolipram for PET imaging phosphodiesterase-4:in vivobinding, metabolism, and dosimetry studies in rats,”Nuclear Medicine and Biology, 28 (2001) 347-358.
Egawa et al., “Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats,”Jpn J Pharmacol, Nov. 1997, 75 (3):275-81.
Schmiechen et al., “Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase,”Psychopharmacology, (Berl) 1990; 102 (1): 17-20.
Marivet et al., “Inhibition of Cyclic Adenosine-3′,5′-monophosphate Phosphodiesterase from Vascular Smooth Muscle by Rolipram Analogues,”J. Med. Chem., 1989, 32, 1450-1457.
Morgan et al., “Biochemical Pharmacology (1993)”, 45(12), 2373-80, pp. 23-27, CAS Abstract Only.
Conticello Richard
Dunn Robert
Hopper Allen
Kuester Erik
Memory Pharmaceutical Corporation
Millen White Zelano & Branigan P.C.
Solola Taofiq
LandOfFree
Phosphodiesterase 4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphodiesterase 4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiesterase 4 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858978